Clinical Trials in Nashville

Showing 12341-12360 of 17,403 trials

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

NCT00820560

To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.

Solid Tumors and Hematologic Malignancy

Incyte Corporation41 participantsStarted Jan 2005

Aurora, Colorado, United States • Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPhase 3< 1 mile

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

NCT00040183

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.

Pancreatic Cancer

OSI Pharmaceuticals569 participantsStarted Nov 2001

Tucson, Arizona, United States • Springdale, Arkansas, United States • Berkeley, California, United States +137 more locations

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Find Trials by Condition in Nashville

Cognitive Rehabilitation:ACTION Training for Soldiers With Executive Dysfunction

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Alendronate to Prevent Loss of Bronchoprotection in Asthma

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Multi-site Validation and Application of a Consensus DSC-MRI Protocol